Targeted Protein Degradation

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

R&D

Targeting proteins to bring new medicines to patients with f...

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists,

Events

Partner Content

5th Annual Targeted Protein Degradation Summit

Deliver Next Generation Degraders to Patients Faster

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Harnessing the cell's own degradation machinery, with Benedi...

Targeting proteins to bring new medicines to patients with f...

5th Annual Targeted Protein Degradation Summit

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Targeted Protein Degradation

Editor's Picks